MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.74
-0.14
-0.54%
Closed 16:00 09/24 EDT
OPEN
25.66
PREV CLOSE
25.88
HIGH
26.05
LOW
25.17
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
29.77
52 WEEK LOW
12.71
MARKET CAP
3.53B
P/E (TTM)
-94.4241
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 1d ago
Genmab drops 12% on legal dispute with J&J over cancer drug
Genmab (GMAB) down 12% premarket in reaction to the announcement that it was locked in a legal battle with its partner Johnson & Johnson (JNJ) over royalty payments for its key cancer
Seekingalpha · 1d ago
Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq®) for subcutaneous administration utilizing Halozyme's ENHANZE® technology in patients with locally
PR Newswire · 09/17 12:00
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj),
PR Newswire · 09/10 12:01
Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/09 16:30
Halozyme To Present At Upcoming Virtual Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the following investor conferences:
PR Newswire · 09/09 13:01
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic plays like Zscaler (ZS) Palo Alto Networks (PANW), Fortinet (FTNT), Zoom Video (ZM) and DocuSign (DOCU) are good for the longer haul
Seekingalpha · 09/05 12:21
Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference. Dr. Torley will take part in a fireside chat at 10:00 a.m. ET / 07:00 a.m. PT on Wednesday, September
PR Newswire · 09/02 21:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HALO stock price target is 32.73 with a high estimate of 43.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 369
Institutional Holdings: 149.58M
% Owned: 109.16%
Shares Outstanding: 137.03M
TypeInstitutionsShares
Increased
91
12.26M
New
81
4.67M
Decreased
72
11.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Elaine Sun
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Kenneth Kelley
Independent Director
Matthew Posard
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HALO
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.